Skip to content
Sign in
Venture capitalBacked 1 network startup

DS Asset Management

Seoul VC that backed BILIX at seed and Series A (kidney-injury drug); its thesis is undocumented.

Seoul, South Korea
Ticket
—Not published
Assets under management
—
Founded
—
Stages
—
Network startups backed
1
Co-investors
6most often with Alpenroute Asset Management

How they invest

Unknown in the record; repeat investor in BILIX (seed and Series A), indicating Korean biotech conviction.

Stage and ticket

Unknown; seed and Series A participation.

Geography

South Korea.

What makes them say yes

  • Inferred: Korean biotech
  • Inferred: follow-on support
  • Unknown

Red flags

  • Unknown
  • Inferred: non-Korean

Sectors

Not published

Stages

Not published

Geographies

Not published

How to approach

Ask BILIX for an intro.

Portfolio

1 network startup · no other company

BILIX seed and Series A.

Gaps in the portfolio

  • No other Korean biotech in the network

Network startups

  • BILIXSWC 2026 Finalist

    KAIST spin-off developing PEGylated bilirubin BX-001N to prevent acute kidney injury after cardiac surgery, now in phase 2a in Korea.

    South Korea · Biotech & life sciences

Network startups that fit

3 analysed

Spatial AI that automates MEP design and BIM-based AR verification for AI data centres and semiconductor fabs.

Korean spatial-AI digital twins at seed: Korean, but non-biotech.

20%confidence

Evidence from the records

  • “Spatial AI / digital twins for industrial construction (MEP)”
  • “South Korea”
Intro path
BILIX (DS portfolio)
First step
Validate mandate via BILIX.

Analyst reading of 21 Nov 2026, from the public record of the network. Method: analyst-ai.

Co-investors

Most often with Alpenroute Asset Management, Estech Pharma, and IBK (Industrial Bank of Korea)

Sources

  1. 1thevc.kr/bilix/fundings

Profile compiled from public sources. Unknown fields are left empty rather than estimated.